Sanofi improves outlook on strength of bestseller Dupixent / Photo: Thomas SAMSON - AFP
-
French businessman takes over 2030 Winter Olympics amid leadership turmoil
-
VW says 'no time to lose' to slash costs after 5.8 billion euro loss
-
Stock markets diverge on corporate earnings, tech jitters
-
Oil majors reap bumper profits as Mideast war drives prices
-
TotalEnergies profit hits record on high oil prices
-
Taiwan says Pakistan briefly closed airspace to Taiwanese flights
-
Afghanistan opium poppy cultivation surges despite Taliban govt ban: UN
-
Samsung logs record quarterly profits despite investor AI jitters
-
Microsoft beats expectations fueled by Azure cloud business
-
Shares in Google owner Alphabet plummet on profit miss, ad slowdown
-
Shares in Google owner Alphabet sink on profit miss, ad slowdown
-
US Fed holds interest rates steady despite 'too high' inflation
-
Pioneering US labor leader Dolores Huerta dies at 96
-
Airbus aims for record deliveries despite disappointing quarter
-
US Fed holds interest rates steady despite surging inflation
-
Real Madrid, La Liga apology over Mbappe shows power of Chinese market
-
US labor leader Dolores Huerta dead: family
-
'Cruise for life' strands passengers in Cambodia as operator goes bust
-
French firm Safran helps build aircraft wings of the future in UK factory
-
Canada hikes rates to contain oil price surge caused by Iran war
-
World Bank warns of worsening food insecurity as commodity prices soar
-
Nintendo producer 'all nervous' as Zelda classic remake hits shelves
Sanofi improves outlook on strength of bestseller Dupixent
French drug maker Sanofi has revised its outlook for 2022 upwards after reporting strong sales growth in the third quarter on Friday.
While Sanofi faced struggles in producing a jab against Covid, its Dupixent drug, which treats conditions including asthma and eczema, has been a huge success.
In Q3, sales of Dupixent exceeded the two billion euros mark for the first time, Sanofi said in a statement.
The pharmaceutical giant was also boosted by nearly two billion euros of sales for its flu vaccines, as many countries prepare for the peak winter flu season.
Sanofi said between July and the end of September, net profit fell 10 percent to two billion euros ($2 billion) due to impairments.
But without exceptional items net profit jumped 32 percent to 3.6 billion euros, higher than expected by analysts.
And in the first nine months of the year, revenue reached 32.3 billion euros -- an increase of more than 16 percent.
Sanofi now expects earnings per share (EPS) -- a measure of a company's profitability -- of around 16 percent for this year, up from earlier predictions.
D.Goldberg--CPN
